Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988231 | 0.94 | KDM1A (0.51) | KDM1ACHRNA7DPP8DPP9RORC | |
| SCHEMBL17988106 | 0.86 | KDM1A (0.49) | KDM1A | |
| SCHEMBL17988194 | 0.86 | KDM1A (0.49) | KDM1A | |
| SCHEMBL17988166 | 0.85 | KDM1A (0.55) | KDM1A | |
| SCHEMBL25069709 | 0.84 | KDM1A (0.54) | KDM1A | |
| SCHEMBL25069745 | 0.84 | KDM1A (0.54) | KDM1A | |
| SCHEMBL17963501 | 0.84 | KDM1A (0.47) | KDM1A | |
| SCHEMBL17988049 | 0.84 | KDM1A (0.57) | KDM1A | |
| SCHEMBL17988148 | 0.83 | KDM1A (0.55) | KDM1ARORC | |
| SCHEMBL17988165 | 0.83 | KDM1A (0.51) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301253-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3250552-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2016123387-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301253-B2 | Therapeutic compounds and uses thereof | KDM1B, HDAC1, DOT1L | KDM1A 7/4885CHRNA7 2037/4885DPP8 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.